Abstract: According to one embodiment, a particle-bound lipid nanoparticles includes a biodegradable lipid nanoparticle, a particle bound to an outer surface of the lipid nanoparticle, and an active substance bound to a surface of the particle.

Abstract: A flow path structure according to an embodiment includes three groups of flow paths connected by branch and merging portions. The first group connects to the second group via a branch portion, and the second group connects to the third group via a merging portion. The branch portion has openings on both the first and second group sides, while the merging portion has openings on both the second and third group sides. If the first group has N flow paths and the second group has M flow paths (where M is N or more), the total opening area of the second group's branch openings is at most M/N times that of the first group's branch openings. Additionally, at least one merging opening in the second group is equal to or smaller than at least one merging opening in the third group.

Abstract: Provided are a lipid particle with high biodegradability, high biocompatibility, a high active agent introducibility, low cytotoxicity, and the like, a composition and a kit which use the lipid particle, and a method of delivering an active agent to a cell. The lipid particle according to the present embodiment comprises: a compound represented by the following Formula (a), Mal-La1-(OCH2CH2)na—O-La2Ra2??(a) (in the formula, Mal is a maleimide group, La1 is an unsubstituted hydrocarbon group, or a substituted hydrocarbon group, La2 is a trivalent hydrocarbon group that does not contain phosphorus, Ra's are a hydrocarbon group containing at least one ester bond at a predetermined position, and na is a number of 1 or more); and an active agent.

Abstract: According to one embodiment, a target cell preparation method includes forming a first water-in-oil droplet containing source cells by mixing an aqueous solution containing source cells with an oil phase, forming a second water-in-oil droplet containing liposomes by mixing a liposomal aqueous solution encapsulating an active agent with an oil phase, fusing the formed first water-in-oil droplet with the second water-in-oil droplet, and introducing the active agent into the source cells in the fused droplet.

Abstract: According to one embodiment, a lipid composition is for delivering an objective substance to a target cell. The composition is contacted with the target cell under an environment of 37° C. or higher. The composition includes a substance delivery carrier having lipid particle and an objective substance encapsulated in the lipid particle. The lipid particle constitutes a liposome and includes FFT-10 and/or FFT-20 as constituents thereof.

Abstract: According to one embodiment, method of identifying feature of test body is provided. The method includes measuring a mutation-specific concentration of at least one miRNA contained in the test body, correcting a value of the mutation-specific concentration, and determining whether the test body is a cancer or a non-cancer one using an increase or decrease in the corrected mutation-specific concentration as index.

Abstract: An analysis method may determine the presence of affection of at least any one of breast cancer, pancreatic cancer, lung cancer, gastric cancer, and colorectal cancer. The analysis method may include quantifying at least any one of hsa-miR-205-5p, hsa-miR-30e-5p, hsa-miR-106b-5p, hsa-miR-3613-5p, hsa-miR-483-5p, hsa-miR-574-3p, hsa-miR-125b-5p, hsa-miR-223-5p, hsa-miR-3613-3p, hsa-miR-941, hsa-miR-324-3p, hsa-miR-193a-5p, hsa-miR-4433a-3p, hsa-miR-29c-3p, hsa-miR-190a-5p, hsa-miR-885-5p, hsa-miR-194-5p, hsa-miR-29a-3p, hsa-miR-142-5p, hsa-miR-142-3p, hsa-miR-122-5p, hsa-miR-34a-5p, and hsa-miR-375-3p in a sample derived from an object.

Abstract: Provided is an examination method wherein a measurement target is produced in a reaction field within a container and reacted with a reagent to cause light emission which is received, and the optical characteristics thereof detected by a detection unit. The reaction field contains a plurality of pieces in a solution in which the reagent dissolves, the pieces being capable of adsorbing the reagent and gradually releasing the adsorbed reagent for reaction with the measurement target. The container is arranged on the detection unit such that the detection unit faces the reaction field.

Abstract: According to one embodiment, a flow channel structure includes a first flow channel, a second flow channel, a third flow channel, a first merging portion that connects one end of the first flow channel, one end of the second flow channel, and one end of the third flow channel to one another, a fourth flow channel, a fifth flow channel, and a second merging portion that connects the other end of the third flow channel, one side end of the fourth flow channel, and one end of the fifth flow channel to one another. The one end of the first flow channel of the flow channel structure has a first shallow portion shallower than the first merging portion, and the one end of the fourth flow channel has a second shallow portion shallower than the second merging portion.

Abstract: According to one embodiment, a method for analyzing the probability of suffering from cancer in a subject is provided. The method includes counting the number of types of RNA in a sample derived from the subject with respect to the types of RNAs in which sequence variation based on RNA editing exists in comparison with a reference sequence, and determining the probability of suffering from cancer in the subject by using the number of types of RNAs obtained as an index.

Abstract: The present embodiment provides a compound represented by the formula (1): Q-CHR2??(1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Abstract: According to one embodiment, a flow channel structure may include a first flow channel, and a second flow channel that joins the first flow channel. An end of the second flow channel close to the first flow channel has a first region having a depth shallower than a depth of the first flow channel.

Abstract: A flow channel structure for removing a foreign substance, including a first flow channel, where the first flow channel has a first region having a depth shallower than a depth of another region. A method for removing a foreign substance in a fluid, including flowing the fluid to the first flow channel of the flow channel structure for removing a foreign substance.

Abstract: According to one embodiment, a vector set includes a first vector and a second vector. The first vector includes a transposase target sequence, a first promoter sequence ligated to downstream of the transposase target sequence, and a first reporter gene ligated to downstream of the first promoter sequence. The second vector includes a 5?-side transposase recognition sequence, a 3?-side transposase recognition sequence, and a first enhancer sequence arranged therebetween.

Abstract: According to one embodiment, a method for manufacturing a lipid particle including a drug, the method includes cooling a solution containing the lipid particle including the drug at a rate of less than or equal to 1° C. per minute.

Abstract: The present embodiment provides a compound represented by the formula (1): Q-CHR2??(1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Abstract: According to one embodiment, a set of nucleic acid constructs which detects a DNA homologous recombination deficiency includes a first nucleic acid construct and a second nucleic acid construct. The first nucleic acid construct includes a first promoter sequence and a cleaved Cre gene ligated to downstream of the first promoter sequence. The second nucleic acid construct includes a second promoter sequence, a first loxP sequence ligated to downstream of the second promoter sequence, a reporter gene ligated to downstream of the first loxP sequence, and a second loxP sequence ligated to downstream of the reporter gene.

Abstract: According to one embodiment, a substance delivery carrier and a composition are used for delivering an intended substance to a myeloid tumor cell. The substance delivery carrier has a lipid particle, and an intended substance encapsulated in the lipid particle. The lipid particle contains, as a constituent thereof, at least a first lipid represented by formula (I).

Abstract: The present embodiment provides a compound represented by the formula (1): Q-CHR2??(1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Abstract: According to one embodiment, a nucleic acid construct is used for detecting an estrogen-sensitive cell. The nucleic acid construct includes an enhancer sequence, a promoter sequence and a reporter gene. The enhancer sequence includes at least an ERE sequence and at least a XRE sequence. The promoter sequence is ligated to downstream of the enhancer sequence. The reporter gene is ligated to downstream of the promoter sequence.